Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system

Molecular Pharmacology

Volumn 64, Issue 3, 2003, Pages 533-546

  Maurice, Donald H ^a   Palmer, Daniel ^a,b   Tilley, Douglas G ^a   Dunkerley, Heather A ^a   Netherton, Stuart J ^a   Raymond, Daniel R ^a   Elbatarny, Hisham S ^a   Jimmo, Sandra L ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE;

CARDIOVASCULAR SYSTEM; CELL FUNCTION; CELL METABOLISM; CELL MOTILITY; CELL TYPE; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; VASCULAR SMOOTH MUSCLE;

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ANIMALS; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS;

EID: 0042355363     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.3.533     Document Type: Short Survey

References (111)

1. Abi-Gerges N, Ji GJ, Lu ZJ, Fischmeister R, Hescheler J, and Fleischmann BK (2000) Functional expression and regulation of the hyperpolarization activated non-selective cation current in embryonic stem cell-derived cardiomyocytes. J Physiol (Lond) 523:377-389.
2. Ammendola A, Geiselhoringer A, Hofmann F, and Schlossmann J (2001) Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase Iβ. J Biol Chem 276:24153-24159.
3. Antoni FA (2000) Molecular diversity of cyclic AMP signalling. Front Neuroendocrinol 21:103-132.
4. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, and Pellikka PA (2002) Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. J Am Med Assoc 287:719-725.
5. Ashikaga T, Strada SJ, and Thompson WJ (1997) Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells. Biochem Pharmacol 54:1071-1079.
6. Baillie G, MacKenzie SJ, and Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60:1100-1111.
7. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, and Houslay MD (2003) Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100:940-945.
8. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748.
9. Beavo JA and Reifsnyder DH (1990) Primary sequence of cyclic-nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155.
10. Blease K, Burke-Gaffney A, and Hellewell PG (1998) Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124:229-237.
11. Bode DC, Kanter JR, and Brunton LL (1991) Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ Res 68:1070-1079.
12. Buxton IL and Brunton LL (1985) Beta-adrenergic receptor subtypes and subcellular compartmentation of cyclic AMP and cyclic AMP-dependent protein kinase in rabbit cardiomyocytes. Biochem Int 11:137-144.
13. Chini CC, Grande JP, Chini EN, and Dousa TP (1997) Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem 272:9854-9859.
14. Choi YH, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello VC, and Movsesian MA (2001) Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41-50.
15. Conti M (2000) Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol 14:1317-1327.
16. Conti M and Jin SLC (2000) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38.
17. Conti M, Nemoz G, Sette C, and Vicini E (1995) Recent progress in understanding the hormonal-regulation of phosphodiesterases. Endocrine Rev 16:370-389.
18. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
19. Corbin JD and Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453-459.
20. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, and Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature (Lond) 396:474-477.
21. Defouw LM and Defouw DO (2001) Differential phosphodiesterase activity contributes to restrictive endothelial barrier function during angiogenesis. Microvascular Research 62:263-270.
22. de Nucci G, Gryglewski RJ, Warner TD, and Vane JR (1988) Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 85:2334-2338.
23. Dickinson NT, Jang EK, and Haslam RJ (1997) Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 323:371-377.
24. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, and Scott JD (2001) MAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO (Eur Mol Biol Organ) J 20:1921-1930.
25. Dunkerley HA, Tilley DG, Palmer D, Liu HG, Jimmo SL, and Maurice DH (2002) Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol 61:1033-1040.
26. Eckly AE and Lugnier C (1994) Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol 113:445-450.
27. Francis SH, Turko IV, and Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52.
28. Galie N, Manes A, and Branzi A (2002) Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis 45:213-224.
29. Garbers DL (1999) The guanylyl cyclase receptors. Methods 19:477-484.
30. Giembycz MA (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10:1361-1379.
31. Giordano D, De Stefano ME, Citro G, Modica A, and Giorgi M (2001) Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 1539:16-27.
32. Han P, Werber J, Surana M, Fleischer N, and Michaeli T (1999) The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem 274:22337-22344.
33. Hanoune J and Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174.
34. Hansen G, Jin S, Umetsu DT, and Conti M (2000) Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97:6751-6756.
35. Haynes J, Killilea DW, Peterson PD, and Thompson WJ (1996) Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3′, 5′-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther 276:752-757.
36. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18.
37. Houslay MD and Kolch W (2000) Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-668.
38. Houslay MD, Sullivan M, and Bolger GB (1998) The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 44:225-342.
39. Inoue Y, Toga K, Sudo T, Tachibana K, Tochizawa S, Kimura Y, Yoshida Y, and Hidaka H (2000) Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. Br J Pharmacol 130:231-241.
40. Jang EK, Davidson MM, Crankshaw D, and Haslam RJ (1993) Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: Roles of cGMP and cAMP. Eur J Pharmacol 250:477-481.
41. Jaworsky DE, Matsuzaki O, Borisy FF, and Ronnett GV (1995) Calcium modulates the rapid kinetics of the odorant-induced cyclic-AMP signal in rat olfactory cilia. J Neuroscience 15:310-318.
42. Juilfs DM, Fulle HJ, Zhao AZ, Houslay MD, Garbers DL, and Beavo JA (1997) A subset of olfactory neurons that selectively express cGMP-stimulated phosphodiesterase (PDE2) and guanylyl cyclase-D define a unique olfactory signal transduction pathway. Proc Natl Acad Sci USA 94:3388-3395.
43. Kakkar R, Raju RVS, and Sharma RK (1999) Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 55:1164-1186.
44. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, and Graybiel AM (1998) A family of cAMP-binding proteins that directly activate Rapl. Science (Wash DC) 282:2275-2279.
45. Keravis T, Komas N, and Lugnier C (2000) Cyclic nucleotide hydrolysis in bovine aortic endothelial cells in culture: differential regulation in cobblestone and spindle phenotypes. J Vasc Res 37:235-249.
46. Kim D, Rybalkin SD, Pi XC, Wang YN, Zhang CX, Munzel T, Beavo JA, Berk BC, and Yan C (2001) Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338-2343.
47. Klein C (2002) Nitric oxide and the other cyclic nucleotide. Cell Signal 14:493-498.
48. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, Scotland G, Huston E, Houslay MD, and Krause EG (1997) Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 29:3135-3146.
49. Lincoln TM, Komalavilas P, Boerth NJ, MacMillan-Crow LA, and Cornwell TL (1995) cGMP signaling through cAMP- and cGMP-dependent protein kinases. Adv Pharmacol 34:305-322.
50. Lindgren S, Andersson KE, Belfrage P, Degerman E, and Manganiello VC (1989) Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol Toxicol 64:440-445.
51. Liu H and Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510.
52. Liu H and Maurice DH (1999a) Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274:10557-10565.
53. Liu H, Palmer D, Jimmo SL, Tilley DG, Dunkerley HA, Pang SC, and Maurice DH (2000) Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 275:26615-26624.
54. Liu HG and Maurice DH (1999b) Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J Biol Chem 274:10557-10565.
55. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, et al. (1998) Isolation and characterization of CDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139-147.
56. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, and Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-413.
57. Lugnier C and Schini VB (1990) Characterization of cyclic-nucleotide phosphodiesterases from cultured bovine aortic endothelial-cells. Biochem Pharmacol 39:75-84.
58. Manganiello VC and Degerman E (1999) Cyclic nucleotide phosphodiesterases: diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemost 82:407-411.
59. Marchese A, George SR, Kolakowski LF, Lynch KR, and O'Dowd BF (1999) Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol Sci 20:370-375.
60. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WGJ, and Beavo JA (2002) The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 99:13260-13265.
61. Maurice DH, Crankshaw D, and Haslam RJ (1991) Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol 192:235-242.
62. Maurice DH and Haslam RJ (1990a) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671-681.
63. Maurice DH and Haslam RJ (1990b) Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 191:471-475.
64. McAllister-Lucas LM, Haik TL, Colbran JL, Sonnenburg WK, Seger D, Turko IV, Beavo JA, Francis SH, and Corbin JD (1995) An essential aspartic acid at each of two allosteric cGMP-binding sites of a cGMP-specific phosphodiesterase. J Biol Chem 270:30671-30679.
65. Mery PF, Pavoine C, Pecker F, and Fischmeister R (1995) Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 48:121-130.
66. Michel JJC and Scott JD (2002) AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 42:235-257.
67. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, and Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398-2403.
68. Movsesian MA (2000) Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure. Expert Opin Investig Drugs 9:963-973.
69. Movsesian MA (2002) PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes. Basic Res Cardiol 97 Suppl 1:183-190.
70. Murray F, MacLean MR, and Pyne NJ (2002) Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137:1187-1194.
71. Nadal-Ginard B, Kajstura J, Leri A, and Anversa P (2003) Myocyte death, growth and regeneration in cardiac hypertrophy and failure. Circ Res 92:139-150.
72. Netherton SJ, Jimmo SL, Palmer D, Tilley DG, Dunkerley HA, Raymond DR, Russell JC, Absher PM, Sage EH, Vernon RB, et al. (2002) Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-Cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. Diabetes 51:1194-1200.
73. Osinski MT, Rauch BH, and Schror K (2001) Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044-1050.
74. Osinski MT and Schror K (2000) Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: role of protein kinase A in vascular smooth muscle cell mitogenesis. Biochem Pharmacol 60:381-387.
75. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, et al. (1991) Effect of oral milrinone on mortality in severe chronic heart-failure. N Engl J Med 325:1468-1475.
76. Palmer D and Maurice DH (2000) Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58:247-252.
77. Palmer D, Tsoi K, and Maurice DH (1998) Synergistic Inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ Res 82:852-861.
78. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, and Polson JB (1994) Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 48:827-835.
79. Pang DC (1992) Tissue and species specificity of cardiac cAMP-phosphodiesterase inhibitors. Adv Second Messenger Phosphoprotein Res 25:307-320.
80. 2-adrenergic receptors by β-arrestins. Science (Wash DC) 298:834-836.
81. Polson JB and Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403-427.
82. Regan CP, Adam PJ, Madsen CS, and Owens GK (2000) Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury. J Clin Investig 106:1139-1147.
83. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, and Bondy CA (1995) Distinctive anatomical patterns of gene-expression for cGMP-inhibited cyclic-nucleotide phosphodiesterases. J Clin Investig 95:1528-1538.
84. Rose RJ, Liu H, Palmer D, and Maurice DH (1997) Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity. Br J Pharmacol 122:233-240.
85. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, and Loughney K (1997) Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase. Gene 191:89-95.
86. Rubin CS (1994) A kinase anchor proteins and the intracellular targeting of signals carried by cyclic-AMP. Biochim Biophys Acta 1224:467-479.
87. Rybalkin SD and Bornfeldt KE (1999) Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82:424-434.
88. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, and Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Investig 100:2611-2621.
89. Rybalkin SD, Rybalkina I, Beavo JA, and Bornfeldt KE (2002) cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151-157.
90. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, and Beavo JA (2003) PDE5 Is converted to an activated state upon cGMP binding to the GAF A domain. EMBO (Eur Mol Biol Organ) J 22:469-478.
91. Sadhu K, Hensley K, Florio VA, and Wolda SL (1999) Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47:895-905.
92. Schoeffter P, Lugnier C, Demesy-Waeldele F, and Stoclet JC (1987) Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol 36:3965-3972.
93. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, and Kass DA (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15:1718-1726.
94. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, and Manganiello V (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277.
95. Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, and Manganiello VC (2000) Membrane Localization of Cyclic Nucleotide Phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275:38749-38761.
96. Soderling SH and Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12:174-179.
97. Souness JE, Hassall GA, and Parrott DP (1992) Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol 44:857-866.
98. Suttorp N, Weber U, Welsch T, and Schudt C (1993) Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Investig 91:1421-1428.
99. Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, and Strada SJ (2002) Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol 63:797-807.
100. Thyberg J (1998) Phenotypic: modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol Histopathol 13:871-891.
101. Tilley DG and Maurice DH (2002) Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol Pharmacol 62:497-506.
102. 2+ channel current in human atrial myocytes. J Physiol (Lond) 533:329-340.
103. 2+ current in rat ventricular myocytes. Br J Pharmacol 127:65-74.
104. Vo NK, Gettemy JM, and Coghlan VM (1998) Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs). Biochem Biophys Res Commun 246:831-835.
105. Wallis RM, Corbin JD, Francis SH, and Ellis P (1999) Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83:3C-12C.
106. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, and Movsesian MA (2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277:38072-38078.
107. Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR, Cutler LS, and Epstein PM (1994) A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun 205:1850-1858.
108. Yau KW (1994) Cyclic Nucleotide-gated channels: an expanding new family of ion channels. Proc Natl Acad Sci USA 91:3481-3483.
109. Zhao AZ, Bornfeldt KE, and Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Investig 102:869-873.
110. Zhao AZ, Huan JN, Gupta S, Pal R, and Sahu A (2002) A Phosphatidylinositol 3kinase-phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 5:727-728.
111. 2+/CaM-activated phosphodiesterases: expression and physiological functions. Signal Transduct Health Dis 31:237-251.